[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thymic-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thymic-carcinoma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,54,76,97,124,150,184,206,226,252,278],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100639274","phase-1-target-selected-car-nk-cells-cd30-cd5-or-mesothelin-for-relapsedrefractory-b2-thymoma-or-thymic-carcinoma-100639274",false,"NCT07598955","Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed\u002FRefractory B2 Thymoma or Thymic Carcinoma","A Phase 1\u002F2, Open-Label, Target-Selected Study of Allogeneic CAR-NK Cells Directed to CD30, CD5, or Mesothelin in Patients With Relapsed\u002FRefractory B2 Thymoma or Thymic Carcinoma","SELECT-NK-THYM","Inclusion Criteria:\n\n* Age 18 to 75 years at the time of consent.\n* Histologically confirmed B2 thymoma or thymic carcinoma that is unresectable, metastatic, or recurrent.\n* Relapsed or refractory after at least 1 prior systemic therapy (including a platinum-based regimen for thymic carcinoma when appropriate) or no standard curative option available.\n* Tumor antigen positivity for at least one of the following by central laboratory assessment: CD30, CD5, or mesothelin. Cohort assignment is based on the dominant target (pre-specified algorithm) and feasibility of manufacturing\u002Favailability.\n* Measurable disease per RECIST v1.1 (or evaluable disease if measurable disease is not feasible; to be specified).\n* ECOG performance status 0-1 (0-2 may be permitted in expansion at investigator discretion).\n* Adequate organ function: ANC ≥ 1.0 x 10\\^9\u002FL, platelets ≥ 75 x 10\\^9\u002FL, hemoglobin ≥ 8 g\u002FdL (transfusions allowed), AST\u002FALT ≤ 3 x ULN (≤ 5 x ULN with liver involvement), total bilirubin ≤ 1.5 x ULN (except Gilbert's), creatinine clearance ≥ 50 mL\u002Fmin.\n* Negative pregnancy test for participants of childbearing potential; agreement to use effective contraception.\n* Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n* Active central nervous system involvement by malignancy requiring immediate therapy.\n* Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 90 days or unresolved ≥Grade 2 toxicity from prior cellular therapy.\n* Uncontrolled infection, including active tuberculosis, or uncontrolled hepatitis B or C infection; known uncontrolled HIV infection.\n* Clinically significant autoimmune disease requiring systemic immunosuppression (e.g., \\>10 mg\u002Fday prednisone equivalent) within 14 days of conditioning, except for stable endocrine replacement.\n* Prior allogeneic hematopoietic stem cell transplant with active graft-versus-host disease or ongoing immunosuppression.\n* Significant cardiovascular disease (e.g., NYHA class III\u002FIV heart failure, recent myocardial infarction), uncontrolled arrhythmia, or QTc prolongation felt to increase risk.\n* Pregnancy or breastfeeding.\n* Concurrent participation in another interventional trial with an investigational anticancer agent within 21 days (washout required).\n* Any condition that, in the investigator's judgment, would interfere with safe participation or interpretation of results.","ALL","18 Years","75 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This Phase 1\u002F2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma. Participants undergo centralized tumor antigen assessment (CD30, CD5, and mesothelin). Based on the dominant and clinically actionable antigen expression profile, each participant is assigned to one of three parallel cohorts (CD30-CAR-NK, CD5-CAR-NK, or mesothelin-CAR-NK). All cohorts use the same lymphodepleting conditioning regimen followed by CAR-NK infusion(s).",[29,30],"B2 Thymoma","Thymic Carcinoma",[32,33,34,35,36,37,38,39,40],"CAR-NK","Natural killer cells","Adoptive cell therapy","Thymic epithelial tumor","CD30","CD5","Mesothelin","Biomarker-guided","Solid tumor immunotherapy","RECRUITING","2026-05-14",{"date":44,"type":45},"2026-05-20","ACTUAL",{"date":47,"type":45},"2026-03-02",{"date":49,"type":22},"2028-04-17",{"name":51,"class":52},"Beijing Biotech","INDUSTRY",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":53},"100617900","phase-2-sacituzumab-tirumotecan-in-participants-with-locally-advanced-or-metastatic-thymic-carcinoma-100617900","NCT07324629","Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy","Inclusion Criteria:\n\n* Males or females aged ≥ 18 to ≤ 75 years at the time of signing the Informed Consent Form;\n* Participants with histologically or cytologically confirmed thymic carcinoma, and locally advanced or metastatic thymic carcinoma who are not suitable for curative intent therapy;\n* Participants with advanced thymic carcinoma who have progressed after at least one prior platinum-based chemotherapy;\n* Able to provide a tumor tissue sample at the time of or after the diagnosis of locally advanced or metastatic tumor;\n* At least one measurable target lesion that has not received radiotherapy according to RECIST v1.1;\n* ECOG performance status score of 0 or 1;\n* Expected survival ≥ 12 weeks;\n* Adequate organ and bone marrow function.\n\nExclusion Criteria:\n\n* Participants with histologically or cytologically confirmed thymoma or thymic neuroendocrine tumor;\n* Participants with known metastases to meninges, brainstem metastases, spinal cord metastases and\u002For compression, active or untreated brain metastases;\n* Participants with other malignant tumors within 3 years prior to the first dose;\n* Presence of any of conditions or risk factors related to cardiovascular and cerebrovascular diseases;\n* Uncontrolled systemic disease as judged by the investigator;\n* History of interstitial lung disease\u002Fnoninfectious pneumonitis requiring steroid therapy;\n* Clinically severe pulmonary impairment due to lung disorder;\n* Presence of active hepatitis B or hepatitis C;\n* Known active tuberculosis;\n* Known hypersensitivity to the study drug or any of its components.",{"count":62,"type":22},30,[26],"The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are:\n\n* How effective is drug Sac-TMT in treating Thymic Carcinoma?\n* What adverse events (AEs) do participants have when taking drug Sac-TMT?\n\nParticipants will:\n\n* Progress after at least one platinum-based chemotherapy treatment.\n* Take drug Sac-TMT every 2 weeks.\n* Take tumor response assessments every 6 weeks.",[30],"NOT_YET_RECRUITING","2026-05-05",{"date":69,"type":45},"2026-05-07",{"date":71,"type":22},"2026-06",{"date":73,"type":22},"2028-10",{"name":75,"class":52},"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":53},"100517586","phase-2-neoadjuvant-treatment-for-locally-advanced-thymic-cancer-100517586","NCT06019468","Neoadjuvant Treatment For Locally Advanced Thymic Cancer","Clinical Study of Envolizumab Combined With Radiotherapy for Neoadjuvant Treatment of Locally Advanced Thymic Cancer","Inclusion Criteria:\n\n1. Pathologically confirmed as thymic carcinoma;\n2. Clinical staging III-IVA (TNM staging system), non-myasthenia gravis (MG) patients, expected to undergo surgical resection;\n3. On the day when the subject signs the informed consent form, they are ≥ 18 years old and\\\u003C75 years old, regardless of gender;\n4. The subjects are able to understand the informed consent form, voluntarily participate, and sign the informed consent form;\n5. Subjects who have not received any anti-thymic tumor treatment in the past, including but not limited to systemic chemotherapy, radiotherapy, or immunotherapy (only those who have received traditional Chinese medicine treatment for anti-tumor indications are allowed to be included, and a cleaning period of at least 2 weeks is required);\n6. At least 1 measurable lesion (according to the solid tumor efficacy evaluation standard RECIST V1.1);\n7. Physical fitness score of 0 or 1 (ECOG scoring system of the Eastern Cancer Collaborative Group in the United States);\n8. Female subjects with fertility must have a negative serum pregnancy test within 7 days before the first administration;\n9. Female subjects with fertility or male subjects with partners with fertility agree to use efficient contraceptive measures (with an annual failure rate of less than 1%) from 7 days before the first administration until 24 weeks after the end of administration;\n10. The main organ functions within 7 days before the first administration meet the following standards:\n\n    1. Bone marrow function: hemoglobin ≥ 10.0 g\u002FdL (no blood transfusion received within 28 days before hemoglobin test), absolute neutrophil count ≥ 1.5 × 109\u002FL, platelet count ≥ 100 × 109\u002FL (no platelet transfusion or IL-11 treatment received within 14 days prior to platelet count test);\n    2. Coagulation function: INR and PT\\\u003C1.5 × ULN, APTT ≤ 1.5 × ULN;\n    3. Liver function: transaminases (ALT and AST) ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 × ULN (total bilirubin ≤ 2.5 in subjects with Gilbert's syndrome or liver metastasis) × ULN);\n    4. Renal function: serum creatinine clearance rate ≥ 60 mL\u002Fmin (calculated according to Cockcroft Fault formula);\n    5. Adequate lung function: According to the doctor's judgment, lung function can meet the requirements of thymectomy surgery.\n\nExclusion Criteria:\n\n1. Pathologically confirmed as a thymic neuroendocrine tumor;\n2. Subjects who have undergone major surgical treatment (such as abdominal or thoracic surgery; excluding diagnostic puncture or peripheral vascular pathway replacement surgery) or have not recovered from surgical treatment within 28 days before the administration of this trial;\n3. Within 14 days before the first administration of this study, systemic corticosteroids (≥ 10 mg\u002Fday prednisone, or equivalent amounts of other corticosteroids) or immunosuppressive therapy are required for 7 consecutive days; Excluding inhalation or local application of hormones, or receiving physiological replacement doses of hormone therapy due to adrenal insufficiency; Allow short-term (\\\u003C7 days) use of corticosteroids for prevention (such as contrast agent allergies) or treatment of non-autoimmune diseases (such as delayed hypersensitivity reactions caused by exposure to allergens);\n4. Received live vaccines (including attenuated live vaccines) within 28 days prior to administration in this study;\n5. Previously or currently suffering from interstitial pneumonia\u002Flung disease that requires systemic hormone therapy;\n6. Previously or currently suffering from autoimmune diseases, including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener syndrome (granulomatosis of vasculitis, Graves disease, rheumatoid arthritis, pituitary inflammation, uveitis), autoimmune hepatitis, systemic sclerosis (scleroderma, etc.), Hashimoto's thyroiditis (exceptions see below), autoimmune vasculitis Autoimmune neuropathy (Guillain Barre syndrome), etc. The following cases are excluded: type I diabetes, hypothyroidism with stable hormone replacement therapy (including hypothyroidism caused by autoimmune thyroid disease), psoriasis or vitiligo without systemic treatment;\n7. Other malignant tumors were combined within 5 years before the first administration, excluding cured skin squamous cell carcinoma, basal cell carcinoma, non-muscle invasive bladder cancer, localized low-risk prostate (defined as stage ≤ T2a, Gleason score ≤ 6, and PSA ≤ 10ng\u002FmL at the time of diagnosis of prostate cancer (if measured, patients who have received radical treatment and have no PSA biochemical relapse can participate in this study), and in situ cervical\u002Fbreast cancer;\n8. Have uncontrolled heart, kidney, gastrointestinal tract, infectious diseases and other complications;\n9. Previous history of allogeneic bone marrow or organ transplantation;;\n10. Previously treated with any antibody\u002Fdrug (immune checkpoint) targeting T cell co-regulatory proteins, such as anti PD (L) 1, CTLA-4, 4-1BB, LAG 3, TIM 3, or anti CD127; Previously received anti-tumor vaccine treatment\n11. Previous history of allergic reactions to antibody-based drugs and intolerance (≥ Level 3 NCI-CTCAE V5.0); Any past history of rapid allergic reactions and uncontrollable asthma (i.e. uncontrollable asthma symptoms of 3 or more of the 3 or more characteristics of partially controlled asthma); Previous obvious allergies to drugs (such as severe allergic reactions, immune-mediated hepatotoxicity, immune-mediated thrombocytopenia or anemia);\n12. Pregnant and\u002For lactating women;\n13. Other situations that may affect the safety or compliance of drug treatment in this study, including but not limited to mental illness, uncontrolled large amounts of serous fluid accumulation, or subjects who require repeated drainage (recurrence within 2 weeks after intervention) with moderate to large amounts of serous fluid accumulation, cachexia, etc.",{"count":84,"type":22},25,[26],"The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.",[30],{"date":89,"type":45},"2026-05-08",{"date":91,"type":45},"2023-11-04",{"date":93,"type":22},"2026-12-30",{"name":95,"class":96},"Shanghai Pulmonary Hospital, Shanghai, China","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":53},"100547033","phase-3-postoperative-adjuvant-chemotherapy-for-thymic-cancer-fuscc-thymic-3-100547033","NCT06402708","Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)","Postoperative Adjuvant Treatment for Thymic Cancer With Completed Resection (Radiotherapy vs Chemoradiotherapy): A Prospective, Multicenter, Open-label, Phase III, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Voluntarily participate and sign an informed consent form in writing;\n2. Age range from 18 to 75 years old, regardless of gender;\n3. Within 3 months after the surgery is completed;\n4. Histologically diagnosed with thymic cancer;\n5. Complete resection based on surgical records, pathological reports, and postoperative imaging;\n6. Masaoka stage: I-III\n7. No severe hematopoietic function, heart, lung, liver, kidney dysfunction, or immune deficiency;\n8. White blood cells ≥ 3 × 109\u002FL; Neutrophils ≥ 1.5 × 109\u002FL; Hemoglobin ≥ 10 g\u002FdL; Platelets ≥ 100 × 109\u002FL; Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)\u002FALT (SGPT) ≤ 2.5 times the upper limit of normal value; Creatinine ≤ 1.5 times the upper limit of normal value;\n\nExclusion Criteria:\n\n1. Having a second primary tumor (excluding cured non malignant melanoma of the skin, papillary thyroid carcinoma, stage I seminomatoma, cervical carcinoma in situ, or other curable tumors that have been tumor free for more than 3 years after treatment);\n2. Symptomatic coronary heart disease, left heart failure, uncontrollable seizures, or loss of self-awareness due to mental illness;\n3. Pregnancy and lactation period;\n4. Patients with drug addiction, chronic alcoholism and AIDS;\n5. Researchers believe that participants are not suitable for this experiment.",{"count":105,"type":22},172,[107],"PHASE3","The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are:\n\n1. Does adjuvant chemotherapy decrease disease progression?\n2. Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance?\n\nResearchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not.\n\nParticipants will:\n\n1. Take radiotherapy (50Gy\u002F25f) with or without 4 cycles of chemotherapy (TPF).\n2. Follow up every 3 months in the first two year, and then every 6 months.",[30],[111,112,113,114],"thymic carcinoma","adjuvant treatment","radiotherapy","chemotherapy","2026-04-22",{"date":117,"type":45},"2026-04-27",{"date":119,"type":45},"2024-04-09",{"date":121,"type":22},"2030-05-01",{"name":123,"class":96},"Fudan University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100629819","phase-2-neoadjuvant-adebrelimab-plus-crt-for-locally-advanced-thymic-carcinoma-100629819","NCT07479628","Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma","A Single-Arm, Prospective, Phase II Trial of Adebrelimab Plus Albumin-Bound Paclitaxel, Cisplatin, and Concurrent Radiotherapy for Neoadjuvant Treatment of Locally Advanced Thymic Carcinoma","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 75 years old at the time of signing the informed consent form, both male and female are eligible.\n2. Histologically confirmed thymic carcinoma.\n3. Potentially resectable locally advanced (T3\u002F4NxM0). No previous treatment for thymic carcinoma, including but not limited to surgery, local radiotherapy, chemotherapy, immunotherapy, targeted drug therapy, and other investigational drug therapy.\n4. At least one measurable lesion according to RECIST 1.1 criteria.\n5. ECOG PS score: 0-1.\n6. Expected survival ≥ 3 months.\n7. Important organ functions must meet the following standards:\n\n1\\) Blood routine test: (No blood transfusion or use of G-CSF and other cytokine drugs for correction within 2 weeks before screening);\n\n1. Hemoglobin (HB) ≥ 90 g\u002FL;\n2. Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL;\n3. Platelet count (PLT) ≥ 90×109\u002FL;\n4. White blood cell count (WBC) ≥ 3.0×109\u002FL and \\\u003C 15×109\u002FL; 2) Other tests: (No human albumin injection within 14 days before screening);\n\na) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN; b) Total bilirubin (TBIL) ≤ 1.5×ULN; c) Albumin (ALB) ≥ 30 g\u002FL; d) Creatinine (Cr) ≤ 1.5×ULN, or creatinine clearance rate (CrCL) ≥ 50 mL\u002Fmin (Cockcroft-Gault formula); e) Thyroid stimulating hormone (TSH) ≤ 1×ULN (If TSH is abnormal, FT3\u002FT3 and FT4\u002FT4 levels should also be examined. If FT3\u002FT3 and FT4\u002FT4 are normal, the patient can be enrolled); f) Activated partial thromboplastin time (APTT) ≤ 1.5×ULN, international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5×ULN (No anticoagulant therapy); g) Left ventricular ejection fraction (LVEF) ≥ 50%. 8. Non-surgically sterilized or female patients of childbearing age must have a negative serum pregnancy test within 3 days before the first dose of the study drug and must not be lactating. Female patients of childbearing age or male patients whose partners are of childbearing age must agree to use highly effective contraceptive methods during the study and for 6 months after the last administration of the study drug.\n\n9\\. Patients must voluntarily join this clinical study, sign the informed consent form, have good compliance, and be able to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Patients with pathologies of thymoma or thymic neuroendocrine tumor.\n2. Patients with other malignant tumors within the past 3 years or concurrently, except for those with cured skin basal cell carcinoma, superficial bladder cancer, skin squamous cell carcinoma, cervical carcinoma in situ, and ductal carcinoma in situ of the breast.\n3. Patients with interstitial pneumonia\u002Finterstitial lung disease (excluding those with only imaging changes), those requiring systemic glucocorticoid treatment for pneumonia (such as radiation-induced pneumonia, etc.), those with active pneumonia or severe lung function impairment confirmed by pulmonary function tests.\n4. Patients with any active or known autoimmune diseases (including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, enteritis, multiple sclerosis, vasculitis, glomerulonephritis, uveitis, hypophysitis, hyperthyroidism, etc.). Patients with type 1 diabetes on stable insulin therapy, hypothyroidism requiring only hormone replacement therapy, and skin diseases (such as eczema, vitiligo or psoriasis) that do not require systemic treatment and have not had acute exacerbation within 1 year before screening are allowed to be enrolled. Patients with asthma requiring medical intervention with bronchodilators cannot be included.\n5. Patients with active pulmonary tuberculosis. Those who have received adequate treatment and have stopped anti-tuberculosis treatment for at least 3 months before treatment can be enrolled.\n6. Patients with uncontrolled clinical symptoms or diseases of the heart, such as: (1) New York Heart Association (NYHA) class 2 or higher heart failure (2) Unstable angina pectoris (3) Myocardial infarction within 1 year (4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.\n7. Patients who have experienced severe infections within 1 month before the start of treatment, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.; patients with any active infections, or those with unexplained fever \\> 38.5°C during the screening period or before the first dose.\n8. Patients with a known positive history of human immunodeficiency virus (HIV) test or acquired immune deficiency syndrome (AIDS). Patients with active viral hepatitis (for hepatitis B: positive HBsAg and HBV DNA test value exceeds 500 IU; for hepatitis C: positive HCV antibody and HCV virus titer test value exceeds the upper limit of normal).\n9. Patients with known allergic reactions to adebiralimab or other PD-(L)1 monoclonal antibodies, or with a history of severe allergies to paclitaxel and platinum-based drugs or their prophylactic medications.\n10. Patients who have undergone major surgical procedures, systemic chemotherapy, immunotherapy, or other clinical trial drugs within 4 weeks before treatment; those who have received palliative radiotherapy within 2 weeks before treatment; those who have taken oral molecular targeted drugs and have stopped for less than 5 half-lives before treatment; or those who have used antibiotics within 1 week before treatment; and those who have not recovered from the toxicity and\u002For complications of previous interventions to NCI-CTCAE ≤ grade 1 (except for alopecia and fatigue, and the indicators mentioned in the inclusion criteria).\n11. According to the researcher's judgment, participants with other factors that may affect the research results or lead to the premature termination of this study, such as alcoholism, drug abuse, substance misuse, other serious diseases (including mental disorders) requiring combined treatment, severe laboratory test abnormalities, or those with family or social factors that may affect medication safety, will be excluded.",{"count":132,"type":22},31,[26],"The goal of this clinical trial (Phase II) is to evaluate the efficacy and safety of neoadjuvant Adebrelimab combined with chemoradiation in patients with locally advanced thymic carcinoma. The main questions it aims to answer are:\n\n* Is neoadjuvant therapy with Adebrelimab plus chemoradiation effective?\n* Is this combination treatment safe and tolerable in this patient population?\n\nParticipants will:\n\n* Receive 2-4 cycles of neoadjuvant Adebrelimab combined with a platinum-based chemotherapy regimen (such as carboplatin plus paclitaxel) and concurrent radiotherapy prior to surgery.\n* Undergo re-staging imaging to assess tumor response and determine surgical candidacy.\n* Undergo surgical resection if the tumor is resectable after neoadjuvant treatment.\n* Receive adjuvant Adebrelimab therapy for up to one year following surgery.\n* Undergo regular follow-up visits for safety monitoring and survival assessment.",[30],[111,137,138,139,140],"locally advanced","neoadjuvant","adebrelimab","chemoradiotherapy","2026-03-15",{"date":143,"type":45},"2026-03-18",{"date":145,"type":22},"2026-04-01",{"date":147,"type":22},"2030-03-01",{"name":149,"class":96},"Shanghai Chest Hospital",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":161,"studyType":162,"phases":4,"briefSummary":163,"conditions":164,"keywords":169,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":53},"100618165","electrocautery-resection-combined-with-hithoc-for-thymic-epithelial-tumors-with-pleural-metastasis-100618165","NCT07328074","Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis","Prospective Cohort Study of Electrocautery Resection Combined With Hyperthermic Intrathoracic Chemotherapy for Thymic Epithelial Tumors With Pleural Metastasis","Inclusion Criteria:\n\n* Pathologically confirmed thymic epithelial tumor (TET)\n* Imaging evidence of thymic epithelial tumor with pleural dissemination or recurrence, deemed suitable for HITHOC by multidisciplinary thoracic team\n* Age ≥16 years and ≤80 years\n* American Society of Anesthesiologists (ASA) physical status classification I-II\n* Normal major organ function\n* No history of other malignancies\n* Prior chemotherapy completed \\>4 weeks, radiotherapy \\>6 weeks, immunotherapy \\>6 weeks before enrollment\n* No allergy to cisplatin or doxorubicin\n* Able to understand the study content and provide informed consent\n\nExclusion Criteria:\n\n* Evidence of extrathoracic metastasis on imaging or pathological examination\n* Myasthenia gravis in unstable phase or acute exacerbation\n* Severe systemic comorbidities, such as active infection, poorly controlled diabetes, coagulopathy, bleeding tendency, or ongoing thrombolytic\u002Fanticoagulation therapy\n* Positive serum pregnancy test or lactation (females)\n* History of organ transplantation (including autologous bone marrow transplantation and peripheral blood stem cell transplantation)\n* History of peripheral nervous system disease, significant psychiatric disorder, or central nervous system disease\n* Currently participating in other clinical trials","16 Years","80 Years",{"count":160,"type":22},70,"36 Months","OBSERVATIONAL","The goal of this observational study is to explore the effectiveness of electrocautery resection combined with hyperthermic intrathoracic chemotherapy (HITHOC) in patients with thymic epithelial tumors with pleural metastasis or recurrence. The study aims to:\n\n* Evaluate whether this combined treatment improves event-free survival in patients with pleural metastasis from thymic epithelial tumors\n* Assess the rates of grade ≥3 treatment-related adverse events\n* Examine how this treatment affects patients' quality of life\n\nParticipants will:\n\n* Undergo extended thymectomy with electrocautery resection of pleural metastases\n* Receive two cycles of hyperthermic intrathoracic chemotherapy with cisplatin and doxorubicin at 42-43°C, 2-4 days apart\n* Complete quality of life questionnaires (EQ-5D) at baseline and regular intervals\n* Have regular follow-up visits with imaging and clinical assessments for up to 36 months to monitor for disease recurrence or progression",[165,166,30,167,168],"Thymic Epithelial Tumor","Thymoma","Pleural Metastasis","Pleural Recurrence",[170,171,172,173,174],"Hyperthermic Intrathoracic Chemotherapy","HITHOC","Electrocautery","Cisplatin","Doxorubicin","2026-02-02",{"date":177,"type":45},"2026-02-05",{"date":179,"type":22},"2026-02",{"date":181,"type":22},"2031-02",{"name":183,"class":96},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100535183","phase-2-a-phase-ii-trial-of-sacituzumab-govitecan-in-patients-with-advanced-thymic-epithelial-tumors-100535183","NCT06248515","A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors","A Phase II Parallel Arm Study of SACITUZUMAB GOVITECAN-HZIY in Patients With Advanced Thymoma and Thymic Carcinoma","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years at time of signing informed consent form (ICF)\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients with histologically confirmed advanced thymoma or thymic carcinoma\n* Patients who have experienced disease progression after treatment with at least one prior systemic therapy\n* Measurable disease per RECIST v1.1\n* Availability of pre-treatment tumor tissue (archival or fresh); If archival tissue is not available and a fresh biopsy is not considered safe and medically feasible by the Investigator, the patient may be approved for enrollment after consultation with the Principal Investigator\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n* Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:\n* Absolute neutrophil count (ANC) \\>\u002F= 1.5 x 10\\^9\u002FL (1500\u002FuL) without filgrastim support\n* Platelet count \\>\u002F= 100 x 10\\^9\u002FL (100,000\u002FuL) without transfusion\n* Hemoglobin (Hgb) \\>\u002F= 80 g\u002FL (8 g\u002FdL). Patients may be transfused to meet this criterion.\n* Aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) \\\u003C\u002F= 2.5 x upper limit of normal (ULN), with the following exceptions:\n\n  * Patients with documented liver metastases: AST and ALT \\\u003C\u002F= 5 x ULN\n  * Patients with documented liver or bone metastases: ALP \\\u003C\u002F= 5 x ULN Serum bilirubin \\\u003C\u002F= 1.5 x ULN with the following exception: patients with known Gilbert disease: serum bilirubin \\\u003C\u002F= 3 x ULN\n* Creatinine clearance \\>\u002F= 30 mL\u002Fmin (calculated using the Cockcroft-Gault formula, see Appendix 2)\n* For patients not receiving therapeutic anticoagulation: INR and aPTT \\\u003C\u002F= 1.5 x ULN\n* Patients with human immunodeficiency virus (HIV) on effective anti-retroviral therapy with undetectable viral load are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable or on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below:\n\n  * Women must remain abstinent or use contraceptive methods with a failure rate of \\\u003C 1% per year during the treatment period and for 6 months after the final dose of study treatment. Women must refrain from donating eggs during this same period.\n  * A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (\\>\u002F= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and\u002For uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.\n  * Examples of contraceptive methods with a failure rate of \\> 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:\n\n  * With a female partner of childbearing potential who is not pregnant, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\\u003C 1% per year during the treatment period and for 90 days after the final dose of sacituzumab govitecan-hziy. Men must refrain from donating sperm during this this same period.\n  * With a pregnant female partner, men must remain abstinent or use a condom during the treatment period and 90 days after the final dose of sacituzumab govitecan-hziy to avoid potential exposure to the embryo.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.\n\nExclusion Criteria:\n\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the view of the investigator, contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 6 months after the final dose of study treatment.\n* Symptomatic brain metastasis requiring corticosteroids. Patients with treated brain metastases are eligible.\n* No concurrent therapy with approved or investigational anticancer therapeutics",{"count":192,"type":22},18,[26],"The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy.\n\nThe main question it aims to answer is:\n\n• What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma?\n\nParticipants will:\n\n* receive a fixed dose of 10 mg\u002Fkg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity\n* have regular blood tests, scans, and examinations to monitor their health.\n* have blood and a biopsy of their tumor for research purposes.",[166,30],"2026-01-23",{"date":198,"type":45},"2026-01-27",{"date":200,"type":45},"2024-04-25",{"date":202,"type":22},"2026-12",{"name":204,"class":96},"Georgetown University",4,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":224,"locationsCount":53},"100580562","phase-2-tislelizumab-combined-with-anlotinib-as-second-line-therapy-in-thymoma-and-thymic-carcinoma-100580562","NCT06838910","Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma","Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma: An Open-label, Single-centre, Phase 2 Study","Inclusion Criteria:\n\n1. Age 18-75 years old, gender is not limited.\n2. Histologically or cytologically confirmed thymoma or thymic carcinoma.\n3. Disease progression during or after first-line chemotherapy (with or without immunotherapy).\n4. At least one measurable solid tumor lesion according to RECIST 1.1 criteria.\n5. Estimated survival ≥ 3 months; United States Eastern Cooperative Oncology Group (ECOG) score: 0 or 1 point.\n6. Vital organ function meets the following criteria:\n\n   1. Hematological examination (no use of any blood components and cell growth factors within 14 days prior to initiation of study treatment): i. neutrophil count (ANC) ≥ 1.5×109\u002FL; ii. platelet count (PLT) ≥100 × 109\u002FL; iii. hemoglobin (Hb) ≥80g\u002FL;\n   2. total bilirubin (TBIL) ≤ 1.5× upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5× ULN, serum albumin (ALB) ≥28g\u002FL;\n   3. left ventricular ejection fraction (LVEF) ≥50%;\n7. Female subjects of childbearing potential must have a serum pregnancy test within 7 days prior to the first dose with a negative result; and must be non-lactating; Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to comply with contraceptive requirements from the time of signing the informed consent form until 8 weeks after the end of the last treatment session.\n8. Informed consent was signed.\n\nExclusion Criteria:\n\n1. Prior treatment with anlotinib or any other anti-angiogenesis drugs.\n2. Patients with symptomatic brain metastasis.\n3. Other primary malignancy in the past 5 years, with the exception of: (radical Non-melanoma skin cancer or cured cervical in-situ carcinoma).\n4. Subjects with active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, Crohn's disease, autoimmune thyroiditis.\n5. Severe infections within 4 weeks prior to inclusion.\n6. Any of the following severe acute comorbidities prior to inclusion:\n\n   1. Does not have uncontrolled pleural effusion\u002Fpericardial effusion\u002For ascites as determined by the investigator;\n   2. Unstable angina myocardial infarction or uncontrolled congestive heart failure within 12 months;\n   3. Uncontrollable hypertension;\n   4. Urine routine test protein ≥++, and confirmed 24 hours urine protein\\> 1.0 g;\n7. Imaging shows that the tumor has invaded a vital vessel perimeter or who, in the opinion of the investigator, have a high likelihood of fatal hemorrhage due to tumor invasion of a vital vessel during the follow-up study;\n8. Clinically significant hemoptysis (daily hemoptysis greater than 50ml) within 3 months prior to enrollment; or significant clinically significant bleeding symptoms or defined bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood ++ and above, or suffering from vasculitis;\n9. Major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to inclusion.\n10. Presence of any mental disease or drug abuse disorder that may interfere with subject's ability for being compliant with study requirements.\n11. Known hypersensitivity or allergy to monoclonal antibody.\n12. Is receiving systemic steroid therapy \\\u003C 2 weeks prior to the first dose of trial treatment or receiving any other form of immunosuppressive medication.\n13. Diagnosis of immunodeficiency or undergoing systemic glucocorticoid therapy or any other immunosuppressive therapy that was continued within 2 weeks prior to the first dose.\n14. Participation in another clinical trial within 28 days.\n15. Any condition that, in the opinion of the investigator, would interfere with evaluation or interpretation of patient safety or study results.",{"count":214,"type":22},20,[26],"It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy. The purpose of this study is to evaluate the safety and efficacy of tislelizumab combined with anlotinib as second-line in thymoma and thymic carcinoma.",[30,166],"2025-11-24",{"date":220,"type":45},"2025-12-01",{"date":222,"type":45},"2025-03-31",{"date":93,"type":22},{"name":225,"class":96},"The First Affiliated Hospital with Nanjing Medical University",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":53},"100606912","phase-1-cd70-targeted-car-t-therapy-in-cd70-positive-advanced-solid-tumors-100606912","NCT07181720","CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors","Clinical Study of CD70-Targeted Chimeric Antigen Receptor T Lymphocytes (CAR-T) in Advanced CD70-Positive Malignant Solid Tumors","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender;\n2. Histologically or cytologically confirmed advanced\u002Fmetastatic solid tumors (tumors with positive CD70 expression, confirmed histopathological ly with IHC 3+ score);\n3. Failed or intolerant to standard second-line treatments (at least one of the following: tyrosine kinase inhibitors (TKIs), poly(ADP-ribose) polymerase inhibitors (PARPi), anti-angiogenic therapy; disease progression or inability to tolerate surgery, chemotherapy, radiotherapy, or targeted therapy);\n4. At least one measurable lesion per RECIST 1.1 criteria, with measurable lesions defined as:\n\n   1. Extranodal lesions with a long axis ≥10mm on CT scan;\n   2. Lymph node lesions with a short axis ≥15mm on CT scan;\n   3. CT slice thickness ≤5mm.\n5. ECOG performance status of 0-2 ;\n6. Expected survival ≥12 weeks;\n7. No history of severe psychiatric disorders;\n8. Adequate organ function as defined by the following:\n\n   1. Hematology: White blood cell count \\>2.0×10⁹\u002FL, neutrophils \\>0.8×10⁹\u002FL, lymphocytes \\>0.5×10⁹\u002FL, platelets \\>50×10⁹\u002FL, hemoglobin \\>90g\u002FL;\n   2. Cardiac: Echocardiogram showing left ventricular ejection fraction (LVEF) ≥50%, and ECG with no significant abnormalities;\n   3. Renal: Serum creatinine ≤2.0×ULN;\n   4. Hepatic: ALT and AST ≤3.0×ULN (may be relaxed to ≤5.0×ULN in cases with liver tumor infiltration); total bilirubin ≤2.0×ULN (may be relaxed to ≤3.0×ULN in cases with Gilbert's syndrome or liver tumor infiltration);\n   5. Oxygen saturation ≥92% without supplemental oxygen;\n9. Ability to undergo single or venous blood collection, with no contraindications to cellular collection;\n10. Female subjects must agree to use reliable contraception (excluding fertility awareness methods) from the time of informed consent until 1 year after CAR-T cell infusion;\n11. Subject or authorized guardian agrees to participate in the trial and signs the informed consent form (ICF), indicating understanding of the trial's purpose and procedures and willingness to participate.\n\nExclusion Criteria:\n\n1. Prior treatment with anti-CD70 therapies;\n2. Active\u002Fsymptomatic central nervous system (CNS) metastasis or meningeal metastasis: Subjects with treated brain metastases are eligible if treatment was completed ≥4 weeks prior to screening and there is no evidence of progression on imaging;\n3. Prior treatments within specified time frames:\n\n   1. Participation in other interventional clinical trials within 3 months before cell infusion (for unapproved drugs, the last dose must be ≥3 months prior; for approved drugs, ≥5 half-lives prior to cell infusion);\n   2. Received chemotherapy or targeted therapy within 2 weeks prior to blood collection or within 5 half-lives of the drug (whichever is shorter);\n   3. Received \\>10mg\u002Fday prednisone (or equivalent) within 2 weeks prior to blood collection, unless for adrenal replacement or inhaled\u002Flocal steroids (except for active autoimmune disease);\n   4. Received live attenuated vaccines within 4 weeks prior to screening;\n4. Active infection requiring systemic treatment or uncontrolled infection within 1 week before screening;\n5. History of any other malignancy within the past 3 years, except for treated and stable non-melanoma skin cancer or malignancies treated with curative intent and no evidence of active disease for ≥3 years;\n6. Cardiovascular conditions:\n\n   1. NYHA Class III or IV heart failure;\n   2. Myocardial infarction or coronary artery bypass graft (CABG) within 6 months prior to screening;\n   3. Clinically significant ventricular arrhythmias or unexplained syncope (excluding vasovagal or dehydration);\n   4. Severe non-ischemic cardiomyopathy;\n7. Active or uncontrolled autoimmune diseases such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, etc.;\n8. Positive for HBsAg or HBcAb with elevated HBV DNA in peripheral blood; positive for HCV antibodies with detectable HCV RNA levels; positive for HIV antibodies; positive syphilis test;\n9. Toxicity from prior anti-tumor treatments has not resolved to baseline or ≤grade 1, except for alopecia or peripheral neuropathy;\n10. History of venous thromboembolism (e.g., pulmonary embolism) requiring ongoing anticoagulation treatment, or meeting one of the following criteria:\n\n    1. Severe bleeding (grade 3 or 4) lasting for ≥30 days;\n    2. Post-thrombotic sequelae (e.g., persistent dyspnea and hypoxia) due to venous thromboembolism;\n11. Pregnant or breastfeeding women;\n12. Other conditions that, in the opinion of the investigator, make the subject unsuitable for participation in the trial.",{"count":234,"type":22},90,[25],"This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CD70-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CD70-positive advanced malignancies were obtained and the recommended dose and infusion schedule.",[238,239,240,241,242,30],"Renal Cell Carcinoma (RCC)","Lung Cancer","Anaplastic Thyroid Carcinomas","Ovarian Cancer","Cervical Cancer","2025-09-28",{"date":245,"type":45},"2025-10-02",{"date":247,"type":45},"2025-09-12",{"date":249,"type":22},"2028-05-31",{"name":251,"class":52},"Chongqing Precision Biotech Co., Ltd",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":162,"phases":4,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":53},"100490578","molecular-analysis-and-treatment-options-of-thymic-malignancies-100490578","NCT05667948","Molecular Analysis and Treatment Options of Thymic Malignancies","Molecular Landscape Analysis and Treatment Options for Thymic Epithelial Tumors","Inclusion Criteria:\n\n* Histologically proven diagnosis of thymic malignancies\n* 18 years of age or older\n* Ability to understand and the willingness to sign a written informed consent document",{"count":260,"type":22},500,"Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies.\n\nIn summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.",[165,30,263],"Thymic Cancer",[265,266,114,267,268,269],"thymic malignancy","thymoma","targeted therapy","immunotherapy","molecular landscape","2025-05-20",{"date":272,"type":45},"2025-05-22",{"date":274,"type":45},"2016-01-01",{"date":276,"type":22},"2026-12-31",{"name":149,"class":96},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":162,"phases":4,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":53},"100539292","artificial-intelligence-prediction-tool-in-thymic-epithelial-tumors-100539292","NCT06301945","Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors","Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors","INTHYM","Inclusion Criteria:\n\nParticipants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically:\n\n* Thymoma A\n* Thymoma AB\n* Thymoma B1\n* Thymoma B2\n* Thymoma B3\n* Thymic Carcinoma\n\nInclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model.\n\nRecurrence Criteria:\n\nParticipants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.",{"count":287,"type":22},1020,"Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and\u002For more aggressive subtypes, defined by the WHO histopathological classification.\n\nIn this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.\n\nThe investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.\n\nIn this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.\n\nThe ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.",[165,30,166,290],"Thymoma and Thymic Carcinoma",[292,293],"Artificial Intelligence","Digital pathology","2024-03-26",{"date":296,"type":45},"2024-03-27",{"date":298,"type":45},"2023-08-01",{"date":300,"type":22},"2027-08-01",{"name":302,"class":96},"Erasmus Medical Center"]